Bionano Genomics Announces Participation at the European Association for Cancer Research (EACR) Congress 2022 Featuring OGM Applications for Cancer Research
June 16 2022 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its
participation at the European Association for Cancer Research
(EACR) 2022 Congress with scientific and poster presentations
highlighting the application of OGM for solid tumor analysis and
cancer research.
EACR 2022 is a four-day congress dedicated to
basic, preclinical, and translational cancer research. EACR
sessions will take place June 20-23, 2022 in Seville, Spain.
Bionano will exhibit all of its solutions relevant to cancer
research, including the Saphyr system, NxClinical software, and
expert laboratory services. The latest version of NxClinical
software, version 6.2, includes integrated genomic scar analysis
for homologous recombination deficiency (HRD). This feature
provides a comprehensive, consistent, and automated analysis of
biomarkers from next-generation sequencing (NGS) and microarray
data that can help clinical researchers stratify therapeutic
response across multiple tumor types.
A corporate satellite session, titled “See More,
Know More: Bionano Helps You Go Deeper in the Understanding of Your
Complex Samples,” will feature genomics researchers highlighting
use of OGM in solid tumor analysis. Alicia Bertolotti from Bionano
will present an overview of OGM’s capabilities in high sensitivity
structural variation (SV) detection for cancer research. Dr. Sylvia
Genovese from Bambino Gesù Children’s Hospital will present on the
use of OGM as part of a comprehensive strategy for detection of
pediatric central nervous system (CNS) tumors. Dr. Juan Díaz-Martín
from Institute of Biomedicine of Sevilla (IBiS) will present on
research into SV detection for Ewing sarcoma (ES) prognostic
markers.
Scientific presentations and poster sessions from
Bionano and collaborators include:
Room |
Title |
Presenter |
Presented |
Auditorium 2 + 3 |
See More, Know More: Bionano Helps You Go Deeper in the
Understanding of Your Complex Samples |
Bertolotti A., Genovese S., Díaz-Martín J. |
June 22, 202214:00-14:45 CEST |
Poster |
Title |
Author |
Presented |
Session 1 |
Exploring the Role of Endoglin in the Aggressiveness of Ewing
Sarcoma and Clear Cell Sarcoma |
Amaral A. |
June 21, 202210:15-18:00 CEST |
Session 1 |
Optical Genome Mapping: Unravelling the Genomic Landscape of
Solitary Fibrous Tumor |
Salguero-Aranda C. |
June 21, 202210:15-18:00 CEST |
Session 2 |
Whole-genome Optical Mapping Reveals a Complex Genetic Architecture
Involving Translocations in Pheochromocytomas |
Manakova J. |
June 22, 202210:15-18:00 CEST |
More details on the conference can be found
here.
“We believe the information covered in these EACR
presentations demonstrates the ongoing progress of OGM becoming an
essential tool in the arsenal of cancer researchers,” commented
Erik Holmlin, president and chief executive officer of Bionano.
“These presentations point to the continued expansion of OGM into
clinical research applications for solid tumor analysis and
hematological malignancies where we believe OGM has the potential
to deliver significant advantages to clinicians relative to the
current standard of care.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis
solutions that can enable researchers and clinicians to reveal
answers to challenging questions in biology and medicine. The
Company’s mission is to transform the way the world sees the genome
through OGM solutions, diagnostic services, and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen business,
the Company also provides diagnostic testing for patients with
clinical presentations consistent with autism spectrum disorder and
other neurodevelopmental disabilities. Through its BioDiscovery
business, the Company also offers an industry-leading,
platform-agnostic software solution, which integrates
next-generation sequencing and microarray data designed to provide
analysis, visualization, interpretation and reporting of copy
number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view.
For more information, visit
www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “can,” “believe,” “potential,”
and similar expressions (as well as other words or expressions
referencing future events, conditions, or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses, or current expectations concerning,
among other things, the ability of OGM and NxClinical software to
offer useful clinical research applications for solid tumor
analysis and hematological malignancies or deliver significant
advantages relative to the current standard of care. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of the COVID-19 pandemic on our
business and the global economy; general market conditions; changes
in the competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; the
inability of OGM or NxClinical software to offer useful clinical
research applications for solid tumor analysis and hematological
malignancies or delivery advantages relative to the current
standard of care; future study results contradicting the results
reported in the presentations given and posters made available at
EACR 2022 Congress; changes in our strategic and commercial plans;
our ability to obtain sufficient financing to fund our strategic
plans and commercialization efforts; the ability of medical and
research institutions to obtain funding to support adoption or
continued use of our technologies; and the risks and uncertainties
associated with our business and financial condition in general,
including the risks and uncertainties described in our filings with
the Securities and Exchange Commission, including, without
limitation, our Annual Report on Form 10-K for the year ended
December 31, 2021 and in other filings subsequently made by us with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany
Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy
ConradJuniper Point+1 (858) 366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024